Table 1.
Summary of Reactome pathway analysis data for MoDC proteins exhibiting statistically significant increases >1.5-fold at 6 h vs 0 h and at 24 h vs 6 h. The data indicates the pathway, number of proteins found/number of proteins in the pathway, p-value and FDR. The top 25 pathways are shown with proteins in each group ranked by p-value (lowest first).
| Protein group | Pathway name | Entities | ||
|---|---|---|---|---|
| Found | p-value | FDR | ||
| Up-regulated; 6 h vs 0 h | Interferon signaling | 10/284 | 2.08E-06 | 6.69E-04 |
| Cytokine signaling in the immune system | 15/771 | 7.26E-06 | 0.001 | |
| Interferon α/β signalling | 6/137 | 8.35E-05 | 0.009 | |
| Interleukin-1 processing | 2/7 | 6.45E-04 | 0.031 | |
| DDX58/IFIH1-mediated induction of Interferon-α/β | 4/77 | 7.34E-04 | 0.031 | |
| ISG15 antiviral mechanism | 4/78 | 7.70E-04 | 0.031 | |
| Antiviral mechanism by IFN-stimulated genes | 4/78 | 7.70E-04 | 0.031 | |
| Negative regulators of DDX58/IFIH1 signaling | 3/34 | 7.86E-04 | 0.031 | |
| Clathrin-mediated endocytosis | 4/139 | 0.006 | 0.215 | |
| TRAF6-mediated endocytosis | 2/24 | 0.007 | 0.229 | |
| Termination of translesion DNA synthesis | 2/32 | 0.012 | 0.278 | |
| Cargo recognition for clathrin-mediated endocytosis | 3/99 | 0.015 | 0.278 | |
| Biosynthesis of aspirin-triggered D-series resolvins | 1/3 | 0.016 | 0.278 | |
| Immune system | 19/2226 | 0.016 | 0.278 | |
| Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template | 2/39 | 0.018 | 0.278 | |
| Interleukin-4 and interleukin-13 signaling | 3/111 | 0.021 | 0.278 | |
| Transcriptional activation of cell cycle inhibitor p21 | 1/4 | 0.021 | 0.278 | |
| Biosynthesis of E-series 18®-resolvins | 1/4 | 0.021 | 0.278 | |
| Biosynthesis of D-series resolvins | 1/4 | 0.021 | 0.278 | |
| Interleukin-10 signaling | 2/45 | 0.023 | 0.278 | |
| PKMTs methylate histone lysines | 2/47 | 0.025 | 0.278 | |
| Biosyntheis of E-series 18(S)-resolvins | 1/5 | 0.026 | 0.278 | |
| DNA damage bypass | 2/49 | 0.027 | 0.278 | |
| Synthesis of 15-eicosatetraenoic acid derivatives | 1/6 | 0.031 | 0.278 | |
| Up-regulated; 24 h vs 6 h | Antigen presentation: Folding, assembly and peptide loading of class I MHC | 50/93 | 1.11E-16 | 4.22E-15 |
| Endosomal/vaculolar pathway | 50/79 | 1.11E-16 | 4.22E-15 | |
| Interferon signaling | 63/284 | 1.11E-16 | 4.22E-15 | |
| Interferon gamma signaling | 54/172 | 1.11E-16 | 4.22E-15 | |
| Class I MHC mediated antigen processing and presentation | 54/440 | 1.11E-16 | 4.22E-15 | |
| ER phagosome pathway | 52/152 | 1.11E-16 | 4.22E-15 | |
| Interferon α/β signaling | 57/137 | 1.11E-16 | 4.22E-15 | |
| Antigen processing-cross presentation | 52/168 | 1.11E-16 | 4.22E-15 | |
| Immuno-regulatory interactions between a lymphoid and a non-lymphoid cell | 51/297 | 1.11E-16 | 4.22E-15 | |
| Cytokine signaling in immune system | 68/771 | 1.11E-16 | 4.22E-15 | |
| Adaptive immune system | 56/944 | 1.11E-16 | 4.22E-15 | |
| Immune system | 72/2226 | 1.11E-16 | 4.22E-15 | |
| DAP12 interactions | 5/46 | 1.92E-04 | 0.007 | |
| TBC/RABGAPs | 4/45 | 0.002 | 0.057 | |
| Antiviral mechanism by IFN-stimulated genes | 5/78 | 0.002 | 0.057 | |
| ISG15 antiviral mechanism | 5/78 | 0.002 | 0.057 | |
| Interleukin-9 signaling | 2/9 | 0.005 | 0.124 | |
| Interleukin-21 signaling | 2/10 | 0.006 | 0.147 | |
| Defective GALE can cause epimerase-deficiency galactosemia (EDG) | 1/1 | 0.011 | 0.247 | |
| Defective SLC27A4 causes ichtyosis prematurity syndrome | 1/1 | 0.011 | 0.247 | |
| Interleukin-6 signaling | 2/15 | 0.013 | 0.267 | |
| Signaling by SCF-KIT | 3/44 | 0.014 | 0.273 | |
| The NLRP inflammasome | 2/16 | 0.014 | 0.273 | |
| Signalling by cytosolic FGFR1 fusion | 2/18 | 0.018 | 0.341 | |
| Signaling by PDGF | 3/59 | 0.03 | 0.487 | |